stockrow
Friday 6 November 2026
Export ACXP’s income statement to Excel — free account
Acurx Pharmaceuticals, Inc.
ACXP Healthcare Biotechnology
- EPS
- +72.0%
- Free cash flow
- −2.36%
Quarter to June 2026, against a year earlier
1.07
0.12
+12.63%
Follow ACXP
Alert me
Acurx Pharmaceuticals, Inc. (ACXP) P/E ratio
Acurx Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LGVN Longeveron Inc. compare | n/m |
| SNTI Senti Biosciences, Inc. compare | n/m |
| CNSY Cerenome, Inc. compare | n/m |
| PCSA Heatwurx Inc. compare | n/m |
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | n/m |
| PULM Pulmatrix, Inc. compare | n/m |
| CDIO Cardio Diagnostics Holdings, Inc. compare | n/m |
| ACXP Acurx Pharmaceuticals, Inc. | n/m |
| IMNN Imunon, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)